jardiance a glp 1 MCT2D Continued growth for GLP-1 receptor

Nowhere did the article mention the supplement's potential smelly side effects

Key safety concerns include potential insulin sensitivity effects linked to certain CLA isomers and the possibility that L-carnitine increases TMAO via gut bacteria in some people which has been associated with cardiovascular risk in observational studies

Ab: antibody AE: adverse event ASTCT: American Society for Transplantation and Cellular Therapy CR: complete response CRS: cytokine release syndrome CT: computed tomography CTCAE: Common Terminology Criteria for Adverse Events DoR: duration of response ECOG PS: Eastern Cooperative Oncology Group performance status FL: follicular lymphoma ICANS: immune effector cell-associated neurotoxicity syndrome IRF: independent review facility IV: intravenous IQR: interquartile range NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events NHL: non-Hodgkin lymphoma ORR: objective response rate PET: positron emission tomography PFS: progression-free survival PR: partial response R/R: relapsed/refractory SAE: serious adverse event SD: stable disease USPI: United States Prescribing Information UTI: urinary tract infection ADC: Antibodydrug conjugate AE: Adverse event ALT: Alanine aminotransferase ASCO: American Society of Clinical Oncology BC: Breast cancer BMI: Body mass index C: Cycle CAP: College of American Pathologists CCOD: Clinical cutoff date CDK4/6: Cyclin-dependent kinase 4 and 6 CDx: Companion diagnostic test CI: Confidence interval CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration CTCAE v4.03: Common Terminology Criteria for Adverse Events version 4.03 CTCAE v4: Common Terminology Criteria for Adverse Events version 4 CTCAE v5.0: Common Terminology Criteria for Adverse Events version 5.0 CTCAE: Common Terminology Criteria for Adverse Events ctDNA: Circulating tumor DNA D: Day DOR: Duration of response DPP-4: Dipeptidyl peptidase-4 ECOG PS: Eastern Cooperative Oncology Group performance status eGFR: Estimated glomerular filtration rate ER: Endocrine receptor ESMO: European Society for Medical Oncology ESO: European School of Oncology ET: Endocrine therapy FDA: Food and Drug Administration Fulv: Fulvestrant HbA1c: Hemoglobin A1c HCP: Health care provider/professional HER2: Human epidermal growth factor receptor 2 HR: Hazard ratio or hormone receptor, depending on context i: Inhibitor IM: Intramuscular Inavo: Inavolisib IV: Intravenous mBC: Metastatic breast cancer MedDRA: Medical Dictionary for Regulatory Activities MTD: Maximum tolerated dose mTOR: Mammalian target of rapamycin mut: Mutated NCI: National Cancer Institute NGS: Next-generation sequencing ORR: Overall response rate OS: Overall survival Palbo: Palbociclib PARP: Poly (ADP-ribose) polymerase Pbo: Placebo PCR: Polymerase chain reaction PD: Progressive disease PFS: Progression-free survival PgR: Progesterone receptor PI3K: Phosphatidylinositol 3-kinase PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha PK: Pharmacokinetics PO: By mouth PRO: Patient-reported outcome Q#W: Every # weeks Q4W: Every 4 weeks QD: Daily R: Randomized RECIST v1.1: Response Evaluation Criteria In Solid Tumors version 1.1 SAE: Serious adverse event SGLT2: Sodium-glucose co-transporter 2 SOC: Standard of care T: Type ULN: Upper limit of normal USPI: United States Prescribing Information CD3: Cluster of differentiation 3 TCR: T-cell receptor CD4: Cluster of differentiation 4 CD8: Cluster of differentiation 8 CD226: Cluster of differentiation 226 Ig: Immunoglobulin ITIM: Immunoreceptor tyrosine-based inhibitory motif MHC: Major histocompatibility complex NK: Natural killer PD-1: Programmed cell death protein 1 PD-L1: Programmed death-ligand 1 PVR: Poliovirus receptor TIGIT: T-cell immunoreceptor with Ig and ITIM domains ASTCT: American Society for Transplantation and Cellular Therapy CD20: Cluster of differentiation 20 CR: Complete response CRS: Cytokine release syndrome CT: Computed tomography CTCAE: Common Terminology Criteria for Adverse Events DLBCL: Diffuse large B-cell lymphoma DoCR: Duration of complete response DoR: Duration of response ECOG PS: Eastern Cooperative Oncology Group performance status FL: Follicular lymphoma HGBCL: High-grade B-cell lymphoma ICANS: Immune effector cell-associated neurotoxicity syndrome IRC: Independent Review Committee NOS: Not otherwise specified ORR: Objective response rate PET: Positron emission tomography PMBCL: Primary mediastinal B-cell lymphoma AE: Adverse event Ang2: Angiopoietin-2 ASTCT: American Society for Transplantation and Cellular Therapy ATG: Anti-thymocyte globulin CAR: Chimeric antigen receptor CARTOX: CAR T-cell Therapy-Associated Toxicity CD3: Cluster of differentiation 3 CPAP: Continuous positive airway pressure CRP: C-reactive protein CRS: Cytokine release syndrome CTCAE: Common Terminology Criteria for Adverse Events DIC: Disseminated intravascular coagulation HLH: Hemophagocytic lymphohistiocytosis ICANS: Immune effector cellassociated neurotoxicity syndrome ICU: Intensive care unit IFN-: Interferon-gamma IL: Interleukin INR: International normalized ratio IRR: Infusion-related reaction MAS: Macrophage activation syndrome MSKCC: Memorial Sloan Kettering Cancer Center NO: Nitric oxide PTT: Partial thromboplastin time TNF-: Tumor necrosis factor alpha VWF: von Wilebrand factor AAAAI: American Academy of Allergy Asthma & Immunology DMT: Disease-modifying therapy HCP: Health Care Provider Ig: Immunoglobulin LLN: Lower limit of normal MS: Multiple Sclerosis NK: Natural killer ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis CMSC: Consortium of Multiple Sclerosis Centers ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis FAERS: FDA Adverse Event Reporting System FDA: US Food and Drug Administration Ig: Immunoglobulin LMP: last menstrual cycle MCA: major congenital anomalies MS: Multiple sclerosis OCR: OCREVUS (ocrelizumab) PML: progressive multifocal leukoencephalopathy PPMS: Primary progressive multiple sclerosis RMS: Relapsing multiple sclerosis CD19: Cluster of differentiation 19 CD20: Cluster of differentiation 20 CDC: Centers for Disease Control and Prevention COVID-19: Coronavirus disease of 2019 DMT: Disease-modifying therapy ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis EMA: European Medicines Association FDA: Food and Drug Administration IgG1: Immunoglobulin G1 LMP: Last menstrual period mAb: Monoclonal antibody MCA: Major congenital anomalies MS: Multiple sclerosis OCR: OCREVUS (ocrelizumab) RID: Relative infant dose UCSF: University of California San Francisco URTI: Upper respiratory tract infection UTI: Urinary tract infection ADA: antidrug antibody AE: adverse event AUC: area under the serum concentrationtime curve CCOD: clinical cut-off date CI: confidence interval C max : maximum serum concentration CTCAE: Common Terminology Criteria for Adverse Events EDSS: Expanded Disability Status Scale Gd+: gadolinium-enhancing GMR: geometric mean ratio h: hour IR: injection reaction IV: intravenous LIR: local injection reaction LLOQ: lower limit of quantification MedDRA: Medical Dictionary for Regulatory Activities min: minutes MRI: magnetic resonance imaging MS: multiple sclerosis N/A: not applicable N/E: new/enlarging OCR: ocrelizumab PD: pharmacodynamic PDR: protocol-defined relapse PK: pharmacokinetics PPMS: primary progressive multiple sclerosis PRO: patient-reported outcome rHuPH20: recombinant human hyaluronidase PH20 RMS: relapsing multiple sclerosis RoA: route of administration SC: subcutaneous SIR: systemic injection reaction T max : time to maximum concentration USPI: United States Prescribing Information W: week ABC: activated B-celllike subtype BICR: blinded independent central review CI: confidence interval CNS: central nervous system CR: complete response DLBCL: diffuse large B-cell lymphoma ECOG PS: Eastern Cooperative Oncology Group performance status EFS efficacy : event-free survival for efficacy causes (time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion) EOT: end of treatment GCB: germinal-center B-celllike subtype HGBL: high-grade B-cell lymphoma HHV8: human herpesvirus 8 HR: hazard ratio INV: investigator IPI: International Prognostic Index ITT: intention-to-treat LYSA: Lymphoma Study Association NE: not evaluable NOS: not otherwise specified OS: overall survival PET-CT: positron emission tomography and computed tomography PFS: progression-free survival Pola-R-CHP: polatuzumab plus rituximab, cyclophosphamide, doxorubicin, prednisone R: randomization R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone R-CHP: rituximab plus cyclophosphamide, doxorubicin, prednisone USPI: United States Prescribing Information ARR: Annualized Relapse Rate ART: Assisted Reproductive Technology CI: Confidence Interval DMT: Disease-modifying therapy EDSS: Expanded Disability Status Scale MS: Multiple Sclerosis T: Trimester OR: Odds ratio OB/Gyn: Obstetrics and Gynecology DBPCFC: Double-blind, placebo-controlled food challenge FDA: Food and Drug Administration ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use IgE: Immunoglobulin E NIH: National Institutes of Health OIT: Oral immunotherapy OLE: Open-label extension R: Randomized Description of the pathogenesis of MASH and the specific role of TL1A in driving the chronic inflammation and fibrosis associated with this liver disease

A Scoping Review of the Relationship between Intermittent Fasting and the Human Gut Microbiota: Current Knowledge and Future Directions